Identification

Name
Clindamycin
Accession Number
DB01190  (APRD00566)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Structure
Thumb
Synonyms
  • 7-CDL
  • 7(S)-Chloro-7-deoxylincomycin
  • Cleocin (tn)
  • Clindamicina
  • Clindamycin
  • Clindamycine
  • Clindamycinum
  • Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside
External IDs
U-21,251 / U-21251
Product Ingredients
IngredientUNIICASInChI Key
Clindamycin hydrochlorideT20OQ1YN1W21462-39-5AUODDLQVRAJAJM-XJQDNNTCSA-N
Clindamycin palmitate hydrochlorideVN9A8JM7M725507-04-4GTNDZRUWKHDICY-DJHAJVGHSA-N
Clindamycin phosphateEH6D7113I824729-96-2UFUVLHLTWXBHGZ-KUWMELJBSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CleocinSuppository100 mg/1VaginalPharmacia & Upjohn Inc1999-08-13Not applicableUs
CleocinCream20 mg/gVaginalPharmacia & Upjohn Inc1992-08-11Not applicableUs
CleocinSuppository100 mg/1VaginalU.S. Pharmaceuticals1999-08-13Not applicableUs
Cleocin HydrochlorideCapsule300 mg/1OralPharmacia & Upjohn Inc1970-05-22Not applicableUs
Cleocin HydrochlorideCapsule150 mg/1OralPharmacia & Upjohn Inc1970-05-22Not applicableUs
Cleocin HydrochlorideCapsule75 mg/1OralPharmacia & Upjohn Inc1970-05-22Not applicableUs00009 0331 02 nlmimage10 070803d0
Cleocin PhosphateInjection, solution150 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc2014-04-10Not applicableUs
Cleocin PhosphateInjection, solution6 mg/mLIntravenousPharmacia & Upjohn Inc1990-08-30Not applicableUs
Cleocin PhosphateInjection, solution150 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1972-10-02Not applicableUs
Cleocin PhosphateInjection, solution150 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1972-10-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clindamycinCapsule300 mgOralApotex Corporation2002-02-20Not applicableCanada
Apo-clindamycinCapsule150 mgOralApotex Corporation2002-02-20Not applicableCanada
Auro-clindamycinCapsule300 mgOralAuro Pharma Inc2015-03-02Not applicableCanada
Auro-clindamycinCapsule150 mgOralAuro Pharma Inc2015-03-02Not applicableCanada
Ava-clindamycinCapsule150 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ava-clindamycinCapsule300 mgOralAvanstra Inc2011-08-222014-08-21Canada
CleocinGranule, for solution75 mg/5mLOralPhysicians Total Care, Inc.2007-11-28Not applicableUs
Cleocin PediatricGranule, for solution75 mg/5mLOralPharmacia & Upjohn Inc1986-04-17Not applicableUs
Cleocin PhosphateInjection, solution150 mg/mLIntravenousPharmacia & Upjohn Inc1987-10-16Not applicableUs
Cleocin PhosphateInjection, solution150 mg/mLIntravenousPharmacia & Upjohn Inc1987-10-16Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AcanyaClindamycin phosphate (10 mg/g) + Benzoyl peroxide (25 mg/g)GelTopicalValent Pharmaceuticals North America2010-07-26Not applicableUs
BenzaclinClindamycin phosphate (10 mg/g) + Benzoyl peroxide (50 mg/g)GelTopicalPhysicians Total Care, Inc.2009-08-27Not applicableUs
BenzaclinClindamycin phosphate (10 mg/g) + Benzoyl peroxide (50 mg/g)GelTopicalValeant Pharmaceuticals North America2000-12-21Not applicableUs
Benzaclin Topical GelClindamycin (1 %) + Benzoyl peroxide (5 %)GelTopicalValeant Canada Lp Valeant Canada S.E.C.2004-05-04Not applicableCanada
Biacna Topical GelClindamycin phosphate (1.200 %) + Tretinoin (0.025 %)GelTopicalValeant Canada Lp Valeant Canada S.E.C.2011-05-16Not applicableCanada
Clindamycin - Benzoyl PeroxideClindamycin phosphate (10 mg/g) + Benzoyl peroxide (50 mg/g)GelTopicalPrasco, Laboratories2012-06-27Not applicableUs
Clindamycin and Benzoyl PeroxideClindamycin + Benzoyl peroxideKitTopicalSandoz2017-08-15Not applicableUs
Clindamycin and Benzoyl PeroxideClindamycin + Benzoyl peroxideKitSandoz2017-08-15Not applicableUs
Clindamycin and Benzoyl PeroxideClindamycin phosphate + Benzoyl peroxideKitPerrigo New York Inc.2015-09-22Not applicableUs
Clindamycin and Benzoyl PeroxideClindamycin + Benzoyl peroxideKitTopicalSandoz2017-08-15Not applicableUs
International/Other Brands
Clinimycin (Hayat) / Dalacin C (Pfizer) / Dalacin T Topical Solution (Pfizer) / Zindaclin (Crawford)
Categories
UNII
3U02EL437C
CAS number
18323-44-9
Weight
Average: 424.983
Monoisotopic: 424.179870573
Chemical Formula
C18H33ClN2O5S
InChI Key
KDLRVYVGXIQJDK-AWPVFWJPSA-N
InChI
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
IUPAC Name
(2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboximidic acid
SMILES
[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O

Pharmacology

Indication

For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.

Associated Conditions
Associated Therapies
Pharmacodynamics

Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.

Mechanism of action

Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.

TargetActionsOrganism
A50S ribosomal protein L10
inhibitor
Shigella flexneri
A23S rRNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.

Volume of distribution
Not Available
Protein binding

92-94%

Metabolism

Hepatic

Route of elimination

Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.

Half life

2.4 hours

Clearance
Not Available
Toxicity

Adverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 - 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Clindamycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineClindamycin may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineClindamycin may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Clindamycin.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineClindamycin may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Clindamycin.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clindamycin.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Clindamycin.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clindamycin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clindamycin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Clindamycin.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Clindamycin.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Clindamycin.Experimental
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Clindamycin.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Clindamycin.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clindamycin.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Alaproclate.Experimental
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Clindamycin.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clindamycin.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clindamycin.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Clindamycin.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Clindamycin.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Clindamycin.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clindamycin.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clindamycin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Clindamycin.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clindamycin.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Clindamycin is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Clindamycin.Illicit, Withdrawn
AmiodaroneThe metabolism of Clindamycin can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideClindamycin may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clindamycin.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Clindamycin.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clindamycin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clindamycin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clindamycin.Experimental
AmphetamineClindamycin may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Clindamycin can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Clindamycin.Experimental
ApalutamideThe serum concentration of Clindamycin can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Clindamycin is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Clindamycin can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Clindamycin.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Clindamycin.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Clindamycin is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clindamycin.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Clindamycin is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clindamycin.Approved
AtazanavirThe metabolism of Clindamycin can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Clindamycin.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Clindamycin.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Clindamycin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clindamycin.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Clindamycin.Investigational
AzelastineClindamycin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Clindamycin.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Clindamycin.Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Clindamycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clindamycin.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Clindamycin.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clindamycin.Illicit
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Clindamycin.Investigational
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Clindamycin.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Clindamycin.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Clindamycin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Clindamycin.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Clindamycin.Approved
BenzphetamineClindamycin may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clindamycin.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Clindamycin.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Clindamycin.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Clindamycin.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Clindamycin can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Clindamycin can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Clindamycin.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Clindamycin.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Clindamycin.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clindamycin.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Clindamycin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clindamycin.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Clindamycin.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clindamycin.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clindamycin.Approved, Investigational, Withdrawn
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Clindamycin.Experimental, Illicit
BuprenorphineClindamycin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Clindamycin.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clindamycin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clindamycin.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clindamycin.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Clindamycin.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clindamycin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clindamycin.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Clindamycin.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clindamycin.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Clindamycin.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Clindamycin.Approved, Investigational
CarbamazepineThe metabolism of Clindamycin can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clindamycin.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Clindamycin.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clindamycin.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Clindamycin.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Clindamycin.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clindamycin.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Clindamycin.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Clindamycin.Illicit
CeritinibThe serum concentration of Clindamycin can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clindamycin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clindamycin.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clindamycin.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clindamycin.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clindamycin.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineClindamycin may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Clindamycin.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clindamycin.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clindamycin.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clindamycin.Approved
CilansetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cilansetron.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Clindamycin.Approved
CisaprideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Clindamycin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Clindamycin is combined with Citalopram.Approved
ClarithromycinThe metabolism of Clindamycin can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Clindamycin.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Clindamycin.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Clindamycin.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clindamycin.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clindamycin.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clindamycin.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clindamycin.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Clindamycin.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clindamycin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Clindamycin.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Clindamycin.Approved, Illicit
ClotrimazoleThe metabolism of Clindamycin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Clindamycin.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clindamycin.Approved
CobicistatThe metabolism of Clindamycin can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clindamycin.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Clindamycin.Approved, Investigational
CrizotinibThe metabolism of Clindamycin can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Clindamycin can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Clindamycin.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Clindamycin.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Clindamycin.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clindamycin.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cyclopentamine.Withdrawn
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Clindamycin.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clindamycin.Approved
DabrafenibThe serum concentration of Clindamycin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Clindamycin can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clindamycin.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clindamycin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Clindamycin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Clindamycin can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Clindamycin.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Clindamycin.Approved
DeferasiroxThe serum concentration of Clindamycin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clindamycin can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Clindamycin.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Clindamycin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clindamycin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clindamycin.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clindamycin.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clindamycin.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Clindamycin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clindamycin.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clindamycin.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Clindamycin.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Clindamycin.Investigational
DextroamphetamineClindamycin may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clindamycin.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clindamycin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clindamycin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clindamycin.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clindamycin.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Clindamycin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Clindamycin.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Clindamycin.Experimental
DiethylpropionClindamycin may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Clindamycin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clindamycin.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clindamycin.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clindamycin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clindamycin.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Clindamycin can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clindamycin.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Clindamycin.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Clindamycin.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clindamycin.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clindamycin.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Clindamycin.Experimental
DolasetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Clindamycin is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Clindamycin is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Clindamycin.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clindamycin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Clindamycin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Dotarizine.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Clindamycin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Clindamycin.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Clindamycin.Approved, Investigational
DoxycyclineThe metabolism of Clindamycin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clindamycin.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved, Illicit
DronedaroneThe metabolism of Clindamycin can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clindamycin.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clindamycin.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clindamycin.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Clindamycin.Investigational
EfavirenzThe metabolism of Clindamycin can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clindamycin.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Clindamycin.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Clindamycin.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Clindamycin.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clindamycin.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clindamycin.Approved, Investigational
EnzalutamideThe serum concentration of Clindamycin can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Clindamycin.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clindamycin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clindamycin.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Clindamycin.Approved
ErythromycinThe therapeutic efficacy of Clindamycin can be decreased when used in combination with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clindamycin is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Clindamycin.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Clindamycin.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clindamycin.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clindamycin.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Clindamycin is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Clindamycin.Experimental
EthanolClindamycin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clindamycin.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clindamycin.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clindamycin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clindamycin.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Clindamycin.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clindamycin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clindamycin.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clindamycin.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Clindamycin.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clindamycin.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clindamycin.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Clindamycin.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Clindamycin can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Clindamycin.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Clindamycin.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Clindamycin.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Clindamycin.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Clindamycin.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clindamycin.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clindamycin.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Clindamycin.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Clindamycin.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clindamycin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Clindamycin.Experimental
FluconazoleThe metabolism of Clindamycin can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clindamycin.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clindamycin.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clindamycin.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clindamycin.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clindamycin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clindamycin.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clindamycin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clindamycin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Clindamycin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clindamycin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Clindamycin can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clindamycin.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Clindamycin.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Clindamycin.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Clindamycin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clindamycin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Clindamycin.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Clindamycin.Investigational
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Clindamycin.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Clindamycin.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clindamycin.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Clindamycin.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Clindamycin is combined with GENTAMICIN C1A.Experimental
GepefrineClindamycin may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Clindamycin.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clindamycin.Approved, Illicit
GranisetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clindamycin.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clindamycin.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clindamycin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clindamycin.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Clindamycin.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Clindamycin.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clindamycin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Clindamycin.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Clindamycin is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Clindamycin.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clindamycin.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Clindamycin.Experimental
HydrocodoneClindamycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clindamycin.Approved, Illicit
HydroxyamphetamineClindamycin may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Clindamycin is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Clindamycin.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Clindamycin can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Clindamycin.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clindamycin.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Clindamycin.Investigational
ImatinibThe metabolism of Clindamycin can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clindamycin.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Clindamycin.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Clindamycin can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Clindamycin.Investigational
Iofetamine I-123Clindamycin may decrease the stimulatory activities of Iofetamine I-123.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Clindamycin is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Clindamycin.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Clindamycin.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Clindamycin.Withdrawn
IsavuconazoleThe serum concentration of Clindamycin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Clindamycin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clindamycin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clindamycin.Approved, Vet Approved
IsoniazidThe metabolism of Clindamycin can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Clindamycin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Clindamycin can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Kanamycin.Approved, Investigational, Vet Approved
KaolinKaolin can cause a decrease in the absorption of Clindamycin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clindamycin.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clindamycin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clindamycin.Approved, Investigational
KetoconazoleThe metabolism of Clindamycin can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Clindamycin.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Clindamycin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clindamycin.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Clindamycin.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Clindamycin is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clindamycin.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Clindamycin.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Clindamycin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clindamycin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Clindamycin is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clindamycin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Clindamycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Clindamycin.Approved, Investigational
LisdexamfetamineClindamycin may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Lithium carbonate.Approved
Lithium cationLithium cation may increase the neurotoxic activities of Clindamycin.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clindamycin.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Clindamycin.Experimental
LofexidineThe therapeutic efficacy of Clindamycin can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Clindamycin can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Clindamycin.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clindamycin.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clindamycin.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Clindamycin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clindamycin.Approved
LorpiprazoleThe serum concentration of Clindamycin can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Lortalamine.Experimental
LovastatinThe metabolism of Clindamycin can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clindamycin.Approved
LuliconazoleThe serum concentration of Clindamycin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Clindamycin can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Clindamycin is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clindamycin.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Clindamycin.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Clindamycin is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Clindamycin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clindamycin.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Clindamycin.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Clindamycin.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Clindamycin.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Clindamycin.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clindamycin.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Clindamycin.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clindamycin.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Clindamycin.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clindamycin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Clindamycin.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clindamycin.Approved, Investigational
MephedroneClindamycin may decrease the stimulatory activities of Mephedrone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Clindamycin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Clindamycin.Experimental
MephentermineClindamycin may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Clindamycin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clindamycin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Clindamycin.Experimental
MequitazineClindamycin may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clindamycin.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clindamycin.Approved
MetergolineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clindamycin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clindamycin.Approved, Illicit
MethamphetamineClindamycin may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clindamycin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clindamycin.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Clindamycin.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clindamycin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clindamycin.Approved
MethotrimeprazineClindamycin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clindamycin.Approved, Investigational, Vet Approved
MethoxyphenamineClindamycin may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clindamycin.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Clindamycin.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Clindamycin.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clindamycin.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Clindamycin.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Methysergide.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clindamycin.Approved, Investigational
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Clindamycin.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Clindamycin.Approved, Withdrawn
MetyrosineClindamycin may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Clindamycin.Approved, Investigational
MibefradilThe metabolism of Clindamycin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Clindamycin can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clindamycin.Approved, Illicit
MidomafetamineClindamycin may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Clindamycin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Clindamycin is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Clindamycin.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved, Investigational
MirtazapineClindamycin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Clindamycin can be decreased when it is combined with Mitotane.Approved
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Clindamycin.Approved
MK-212The risk or severity of adverse effects can be increased when Clindamycin is combined with MK-212.Investigational
MMDAClindamycin may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clindamycin.Approved, Investigational
ModafinilThe serum concentration of Clindamycin can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clindamycin.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Clindamycin.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Clindamycin.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clindamycin.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Clindamycin.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Clindamycin.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved, Investigational
NafcillinThe serum concentration of Clindamycin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Clindamycin is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clindamycin.Approved
NaloxoneThe metabolism of Clindamycin can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Clindamycin is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Clindamycin.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Clindamycin is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Clindamycin.Investigational
NelfinavirThe metabolism of Clindamycin can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Clindamycin.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Clindamycin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Clindamycin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Clindamycin can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Clindamycin.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Clindamycin.Experimental
NicardipineThe metabolism of Clindamycin can be decreased when combined with Nicardipine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Nicotine.Approved
NilotinibThe metabolism of Clindamycin can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clindamycin.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clindamycin.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Clindamycin.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Clindamycin.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clindamycin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clindamycin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Clindamycin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clindamycin.Approved, Investigational
OlaparibThe metabolism of Clindamycin can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clindamycin.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clindamycin.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Clindamycin.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clindamycin.Approved, Illicit
OrphenadrineClindamycin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Clindamycin.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clindamycin.Investigational
OsimertinibThe serum concentration of Clindamycin can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Clindamycin.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Clindamycin.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clindamycin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Clindamycin.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Clindamycin.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Clindamycin.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clindamycin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clindamycin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clindamycin.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Clindamycin.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Clindamycin can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clindamycin.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Palonosetron.Approved, Investigational
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Clindamycin.Approved
ParaldehydeClindamycin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Clindamycin.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Clindamycin.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Clindamycin is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Clindamycin.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Penimepicycline.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clindamycin.Approved, Vet Approved
PentobarbitalThe metabolism of Clindamycin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Clindamycin is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Clindamycin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clindamycin.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clindamycin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clindamycin.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Clindamycin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Clindamycin.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Clindamycin.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clindamycin.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Clindamycin.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Clindamycin.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Clindamycin.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Clindamycin.Withdrawn
PhenobarbitalThe metabolism of Clindamycin can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Clindamycin.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Clindamycin.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Clindamycin.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Clindamycin.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Clindamycin.Approved, Illicit
PhenytoinThe metabolism of Clindamycin can be increased when combined with Phenytoin.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Clindamycin is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clindamycin.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Clindamycin.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Clindamycin.Experimental
PindololThe risk or severity of adverse effects can be increased when Clindamycin is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clindamycin.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Clindamycin.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clindamycin.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Clindamycin.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Clindamycin.Approved
PitolisantThe serum concentration of Clindamycin can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Clindamycin.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Clindamycin.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Clindamycin.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clindamycin.Approved
PosaconazoleThe metabolism of Clindamycin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleClindamycin may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clindamycin.Approved, Illicit
PregabalinThe therapeutic efficacy of Clindamycin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Clindamycin.Experimental
PrimidoneThe metabolism of Clindamycin can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clindamycin.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clindamycin.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clindamycin.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Clindamycin.Approved, Investigational
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clindamycin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clindamycin.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Clindamycin.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Clindamycin.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Clindamycin.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Clindamycin.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clindamycin.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Clindamycin.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clindamycin.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Clindamycin.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Clindamycin is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Clindamycin.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Clindamycin.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Puromycin.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Clindamycin.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Clindamycin.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clindamycin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clindamycin.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Clindamycin.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Clindamycin can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Clindamycin.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Clindamycin.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clindamycin is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Ramosetron.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Clindamycin.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clindamycin.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Clindamycin.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Clindamycin.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clindamycin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clindamycin.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Clindamycin is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Clindamycin.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clindamycin.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Clindamycin can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Clindamycin can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Clindamycin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Clindamycin can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Clindamycin.Approved, Investigational
RimexoloneThe metabolism of Clindamycin can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clindamycin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Ritanserin.Investigational
RitobegronClindamycin may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Clindamycin can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Clindamycin.Approved
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Clindamycin.Approved
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Clindamycin.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clindamycin.Vet Approved
RopiniroleClindamycin may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineClindamycin may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Clindamycin is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clindamycin.Approved
SafinamideThe risk or severity of adverse effects can be increased when Clindamycin is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Clindamycin.Withdrawn
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Clindamycin.Approved
SaquinavirThe metabolism of Clindamycin can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Clindamycin.Investigational
SarilumabThe therapeutic efficacy of Clindamycin can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Clindamycin is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clindamycin.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clindamycin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clindamycin.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Clindamycin is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clindamycin.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clindamycin.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Clindamycin.Approved, Illicit, Investigational, Withdrawn
SiltuximabThe serum concentration of Clindamycin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Clindamycin can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved
St. John's WortThe serum concentration of Clindamycin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Clindamycin can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Clindamycin.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Clindamycin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clindamycin.Approved, Investigational
SulpirideClindamycin may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Clindamycin.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Clindamycin.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Clindamycin.Approved, Investigational
SuvorexantClindamycin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Clindamycin.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Clindamycin is combined with Talopram.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Clindamycin.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Clindamycin is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid phosphate is combined with Clindamycin.Approved
TegaserodThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Clindamycin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Clindamycin can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clindamycin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clindamycin.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tetracycline.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tetraethylammonium.Experimental, Investigational
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clindamycin.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Clindamycin.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clindamycin.Investigational
ThalidomideClindamycin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clindamycin.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Clindamycin.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Clindamycin.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Clindamycin.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clindamycin.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Clindamycin.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Clindamycin.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clindamycin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clindamycin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clindamycin.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Clindamycin.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Clindamycin.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clindamycin.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Clindamycin.Experimental
TipranavirThe metabolism of Clindamycin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clindamycin.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Clindamycin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Clindamycin.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clindamycin.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Clindamycin.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Clindamycin.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clindamycin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clindamycin.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Clindamycin.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clindamycin.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Clindamycin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clindamycin.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Clindamycin.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Clindamycin.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Clindamycin.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clindamycin.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Clindamycin.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clindamycin.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Clindamycin.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Clindamycin is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clindamycin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clindamycin.Approved
TroleandomycinThe metabolism of Clindamycin can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Clindamycin is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Clindamycin.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Clindamycin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clindamycin.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Clindamycin.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Vancomycin.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Clindamycin.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clindamycin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Clindamycin.Experimental
VerapamilThe metabolism of Clindamycin can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Clindamycin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Clindamycin.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Clindamycin.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Clindamycin.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Clindamycin.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Clindamycin.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Clindamycin.Experimental
VoriconazoleThe metabolism of Clindamycin can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clindamycin.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Clindamycin is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Clindamycin is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clindamycin.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Clindamycin is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clindamycin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Clindamycin.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Clindamycin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clindamycin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clindamycin.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clindamycin.Approved, Investigational
ZolpidemClindamycin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clindamycin.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clindamycin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clindamycin.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clindamycin.Approved, Investigational
Food Interactions
  • Take with food.

References

Synthesis Reference

Donald E. Ayer, Carl A. Schlagel, Gordon L. Flynn, "Topical clindamycin preparations." U.S. Patent US4018918, issued January, 1971.

US4018918
General References
  1. Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90. [PubMed:17652653]
  2. Klempner MS, Styrt B: Clindamycin uptake by human neutrophils. J Infect Dis. 1981 Nov;144(5):472-9. [PubMed:6171600]
  3. Lamont RF: Can antibiotics prevent preterm birth--the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. [PubMed:15715599]
  4. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. [PubMed:2751277]
External Links
KEGG Drug
D00277
KEGG Compound
C06914
PubChem Compound
446598
PubChem Substance
46506073
ChemSpider
393915
ChEBI
3745
ChEMBL
CHEMBL1753
Therapeutic Targets Database
DAP000409
PharmGKB
PA449035
HET
CLY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clindamycin
ATC Codes
J01FF01 — ClindamycinG01AA10 — ClindamycinD10AF01 — ClindamycinD10AF51 — Clindamycin, combinations
AHFS Codes
  • 84:04.04 — Antibiotics
  • 08:12.28.20 — Lincomycins
PDB Entries
1jzx / 1yjn / 3jz0 / 4v7v
FDA label
Download (151 KB)
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentVaginal Inflammation1
0RecruitingTreatmentOsteomyelitis1
1Active Not RecruitingOtherBacterial Infections1
1CompletedNot AvailableAcne Vulgaris1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceBacterial Infections / BMI >30 kg/m21
1CompletedTreatmentAcne Vulgaris4
1, 2CompletedTreatmentAcne Vulgaris1
2CompletedPreventionSurgical Site Infections1
2CompletedTreatmentAcne Vulgaris1
2CompletedTreatmentInfection caused by staphylococci1
2CompletedTreatmentRash1
2Not Yet RecruitingTreatmentAbdominal Abscess1
2RecruitingTreatmentBacterial Vaginosis Treatment1
2RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
2RecruitingTreatmentPre-Diabetic1
2TerminatedTreatmentOsteomyelitis1
2Unknown StatusTreatmentHip Prosthetic Joint Infection1
2Unknown StatusTreatmentPlasmodium Infections1
2, 3CompletedTreatmentComplicated Intra Abdominal Infections1
2, 3CompletedTreatmentInfection caused by staphylococci1
2, 3CompletedTreatmentRosaceas1
2, 3Not Yet RecruitingTreatmentSymptomatic Periapical Periodontitis1
3CompletedTreatmentAcne2
3CompletedTreatmentAcne Vulgaris9
3CompletedTreatmentAcne / Acne Vulgaris1
3CompletedTreatmentBacterial Vaginosis (BV)1
3CompletedTreatmentDiabetes Mellitus (DM) / Periodontal Pocket / Periodontitis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
3CompletedTreatmentPlasmodium Infections2
3CompletedTreatmentVaginal Inflammation / Vulvovaginitis1
3Not Yet RecruitingTreatmentAcne Vulgaris1
3RecruitingOtherRenal Stones1
3RecruitingPreventionAtrioventricular block complete / Chronic Systolic Heart Failure / Sick Sinus Syndrome / Syncope1
3RecruitingTreatmentAcne Vulgaris1
3RecruitingTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious1
3RecruitingTreatmentStaphylococcus Aureus Infections1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3WithdrawnTreatmentInfection NOS / Skin Diseases1
4Active Not RecruitingTreatmentCellulitis1
4CompletedNot AvailableBacterial Endophthalmitis / Endophthalmitis / Prophylaxy of Post Traumatic Endophthalmitis1
4CompletedNot AvailablePerforated Appendicitis1
4CompletedPreventionBacterial Vaginosis (BV) / Pregnancy / Premature Babies / Premature Births1
4CompletedPreventionEmpyema / Pleural Effusions / Pleuritis1
4CompletedPreventionPregnancy1
4CompletedTreatmentAbscesses / Folliculitis / Infection caused by staphylococci / Staphylococcal Skin Infections1
4CompletedTreatmentAcne1
4CompletedTreatmentAcne Vulgaris12
4CompletedTreatmentAcne Vulgaris / Post Inflammatory Hyperpigmentation1
4CompletedTreatmentAnti-Infective Agents / Bacterial Infections / Breast Implantation1
4CompletedTreatmentFocal Infection, Dental1
4Not Yet RecruitingPreventionFractures, Open / Post-Op Wound Infection1
4RecruitingPreventionPost Operative Wound Infection / Supracondylar Humerus Fractures1
4RecruitingTreatmentBacterial Vaginosis (BV)1
4RecruitingTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
4RecruitingTreatmentSeptic Abortion1
4Unknown StatusTreatmentAcne1
4Unknown StatusTreatmentAcne Vulgaris1
4Unknown StatusTreatmentAmputation Wound / Wound Infections1
4WithdrawnPreventionComplications; Breast Prosthesis, Infection or Inflammation1
4WithdrawnTreatmentPneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentAbscesses / Skin Diseases, Bacterial1
Not AvailableCompletedTreatmentAcne Vulgaris1
Not AvailableCompletedTreatmentCervical Insufficiency1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Toxoplasmosis, Cerebral2
Not AvailableCompletedTreatmentMILD TO SEVERE ACNE VULGARIS1
Not AvailableEnrolling by InvitationTreatmentPartially Edentulous Jaw1
Not AvailableNot Yet RecruitingPreventionCutaneous lesions1
Not AvailableNot Yet RecruitingTreatmentProsthetic Joint Infection1
Not AvailableRecruitingNot AvailableGeneral Surgery1
Not AvailableRecruitingNot AvailableInfertility, Female1
Not AvailableRecruitingPreventionForeskin HIV Susceptibility1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentAbnormal Vaginal Flora / Clindamycin Vs Metronidazole / High Risk Pregnancies for Preterm Labor1
Not AvailableRecruitingTreatmentAnal Fistulas1
Not AvailableRecruitingTreatmentInfection caused by staphylococci1
Not AvailableTerminatedTreatmentAbscess Soft Tissue / Methicillin-resistant Staphylococcus Aureus (MRSA) Infection / Skin Abscess1
Not AvailableTerminatedTreatmentSimple Hand Lacerations1
Not AvailableUnknown StatusPreventionBisphosphonate-Associated Osteonecrosis of the Jaw1
Not AvailableUnknown StatusPreventionDentofacial Deformity1
Not AvailableUnknown StatusTreatmentEndometritis1
Not AvailableUnknown StatusTreatmentHidradenitis Suppurativa (HS)1
Not AvailableWithdrawnTreatmentPeritonsillar Abscess1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Accra Pac Inc.
  • Aidarex Pharmacuticals LLC
  • Ameri-Pac Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Catalent Pharma Solutions
  • Contract Pharm
  • Corepharma LLC
  • Coria Laboratories
  • Coupler Enterprises Inc.
  • Dermik Labs
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dow Pharmaceutical Sciences
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Galderma Laboratories
  • Gallipot
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Innoviant Pharmacy Inc.
  • Inyx Usa Ltd.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Kleen Test Products Corp.
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Nycomed Inc.
  • Ohm Laboratories Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmaderm
  • Pharmedix
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Quality Care
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Sanofi-Aventis Inc.
  • Sirius Labs
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stiefel Labs
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Unimed Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
SuppositoryVaginal100 mg/1
CapsuleOral75 mg/1
Injection, solutionIntramuscular; Intravenous12 mg/mL
Injection, solutionIntramuscular; Intravenous18 mg/mL
Injection, solutionIntramuscular; Intravenous6 mg/mL
Injection, solutionIntravenous12 mg/mL
Injection, solutionIntravenous150 mg/mL
Injection, solutionIntravenous18 mg/mL
Injection, solutionIntravenous6 mg/mL
KitIntramuscular; Intravenous
Kit
SwabTopical10 mg/1
GelTopical1 g/10mL
SuspensionTopical10 mg/mL
InjectionIntravenous300 mg/50mL
InjectionIntravenous600 mg/50mL
InjectionIntravenous900 mg/50mL
Injection, solution, concentrateIntramuscular; Intravenous150 mg/mL
Injection, solution, concentrateIntravenous150 mg/mL
Kit
CapsuleOral150 mg/1
CapsuleOral300 mg/1
Capsule, gelatin coatedOral150 mg/1
Capsule, gelatin coatedOral300 mg/1
Capsule, gelatin coatedOral75 mg/1
LiquidIntramuscular; Intravenous150 mg
SolutionIntravenous150 mg
SolutionIntravenous12 mg
SolutionIntravenous18 mg
SolutionIntravenous6 mg
SolutionOral75 mg/5mL
Granule, for solutionOral75 mg/5mL
Powder, for solutionOral75 mg/5mL
Aerosol, foamTopical10 mg/g
CreamVaginal20 mg/g
GelTopical10 mg/g
Injection, solutionIntramuscular; Intravenous150 mg/mL
Injection, solutionIntravenous300 mg/50mL
Injection, solutionIntravenous600 mg/50mL
Injection, solutionIntravenous900 mg/50mL
LotionTopical10 mg/mL
SolutionTopical10 mg/mL
SolutionTopical11.9 mg/mL
CreamTopical
CreamVaginal100 mg/5g
SwabTopical1 %
Powder, for solutionOral75 mg
SolutionIntramuscular; Intravenous150 mg
SolutionTopical1 %
CreamVaginal20 mg
GelTopical
KitTopical
CapsuleOral150 mg
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Clindagel 1% Gel 75ml Bottle324.48USD bottle
Evoclin 1% Foam 100 gm Can306.79USD can
Clindamycin Phosphate 1% Foam 100 gm Can286.04USD can
Evoclin 1% Foam 50 gm Can207.67USD can
Clindagel 1% Gel 40ml Bottle203.42USD bottle
Clindamycin Phosphate 1% Foam 50 gm Can186.9USD can
Clindamycin Phos-Benzoyl Perox 1-5% Gel 50 gm Jar176.42USD jar
Cleocin-T 1% Gel 60 gm Tube112.84USD tube
Cleocin-T 1% Lotion 60ml Bottle86.09USD bottle
Cleocin-T 60 1% Swab Box82.6USD box
Cleocin 2% Cream 40 gm Tube81.56USD tube
Cleocin 3 100 mg Suppository Box80.05USD box
Cleocin 75 mg/5ml Solution 100ml Bottle78.7USD bottle
Clindamycin hcl crystals74.9USD g
Clindamycin Phosphate 1% Gel 60 gm Tube71.42USD tube
Cleocin-T 1% Solution 60ml Bottle69.29USD bottle
Cleocin-T 1% Gel 30 gm Tube62.98USD tube
Clindamycin Phosphate 2% Cream 40 gm Tube54.99USD tube
Clindamycin Phosphate 60 1% Swab Box47.74USD box
Clindamycin Phosphate 1% Lotion 60ml Bottle46.92USD bottle
Clindesse 2% vaginal cream39.08USD g
Clindamycin Phosphate 1% Gel 30 gm Tube33.41USD tube
Clindamycin Phosphate 1% Solution 60ml Bottle24.07USD bottle
Clindamycin phosphate powdr21.42USD g
Clindamycin Phosphate 1% Solution 30ml Bottle14.99USD bottle
Cleocin hcl 300 mg capsule9.11USD capsule
Clindamycin phos crystals7.73USD g
Evoclin 1% foam4.9USD g
Clindagel 1% gel4.89USD ml
Cleocin 150 mg capsule4.66USD capsule
Dalacin C Phosphate 150 mg/ml4.53USD ml
Clindamycin hcl 300 mg capsule3.98USD capsule
Clindamycin phosphate 1% foam3.59USD g
Clindamycin 150 mg/ml3.48USD ml
Clindamycin (60 & 120 Ml) 150 mg/ml3.41USD ml
Cleocin hcl 150 mg capsule2.79USD capsule
Cleocin hcl 75 mg capsule2.28USD capsule
Dalacin C 300 mg Capsule2.12USD capsule
Cleocin 2% vaginal cream1.97USD g
Clindamycin 150 mg/ml addvan1.97USD ml
Cleocin phos 150 mg/ml vial1.91USD ml
Cleocin t 1% gel1.81USD g
Clindamycin ph 300 mg/2 ml vial1.74USD ml
Clindamax 2% vaginal cream1.37USD g
Clindamycin 2% vaginal cream1.27USD g
Clindamycin hcl 150 mg capsule1.21USD capsule
Clindets 1% pledgets1.1USD each
Dalacin C 150 mg Capsule1.06USD capsule
Apo-Clindamycin 300 mg Capsule1.02USD capsule
Mylan-Clindamycin 300 mg Capsule1.02USD capsule
Novo-Clindamycin 300 mg Capsule1.02USD capsule
Clindamycin ph 9 g/60 ml vial0.93USD ml
Apo-Clindamycin 150 mg Capsule0.51USD capsule
Mylan-Clindamycin 150 mg Capsule0.51USD capsule
Novo-Clindamycin 150 mg Capsule0.51USD capsule
Clinda-derm 1% solution0.4USD ml
Cleocin 900 mg-d5w-galaxy0.37USD ml
Cleocin 600 mg-d5w-galaxy0.3USD ml
Dalacin C Palmitate 15 mg/ml Solution0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5266329No1993-11-302010-11-30Us
US5993856No1997-11-172017-11-17Us
US6387383No2000-08-032020-08-03Us
US7374747No2006-08-092026-08-09Us
US7141237No2004-01-232024-01-23Us
US8288434No2009-08-052029-08-05Us
US8663699No2009-06-032029-06-03Us
US8895070No2009-06-032029-06-03Us
US9078870No2009-06-032029-06-03Us
US6495157No2000-07-202020-07-20Us
US6899890No2003-04-272023-04-27Us
US9504704No2009-06-032029-06-03Us
US9561208No2009-06-032029-06-03Us
US9789057No2006-12-022026-12-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142 [HCl salt]Not Available
water solubility30.6 mg/LNot Available
logP2.16HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.46 mg/mLALOGPS
logP1.59ALOGPS
logP1.09ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)5.91ChemAxon
pKa (Strongest Basic)6.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area105.75 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity106.24 m3·mol-1ChemAxon
Polarizability44.99 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8143
Blood Brain Barrier-0.9697
Caco-2 permeable-0.8236
P-glycoprotein substrateSubstrate0.7653
P-glycoprotein inhibitor INon-inhibitor0.7311
P-glycoprotein inhibitor IIInhibitor0.7894
Renal organic cation transporterNon-inhibitor0.8784
CYP450 2C9 substrateNon-substrate0.8214
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6762
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8876
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9107
Ames testNon AMES toxic0.6967
CarcinogenicityNon-carcinogens0.9172
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.3192 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9887
hERG inhibition (predictor II)Non-inhibitor0.59
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
Alpha amino acid amides / Thioglycosides / Pyrrolidinecarboxamides / Monosaccharides / N-alkylpyrrolidines / Oxanes / Monothioacetals / Trialkylamines / Secondary carboxylic acid amides / Secondary alcohols
show 10 more
Substituents
Proline or derivatives / Alpha-amino acid amide / Glycosyl compound / S-glycosyl compound / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Monosaccharide / Oxane / N-alkylpyrrolidine / Monothioacetal
show 27 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a cent...
Gene Name
rplJ
Uniprot ID
P0A7J6
Uniprot Name
50S ribosomal protein L10
Molecular Weight
17711.38 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [PubMed:11677599]
2. 23S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [PubMed:11677599]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:49